ACADIA PHARMACEUTICALS INC (ACAD) — SEC Financial Statements & Analysis

ACADIA PHARMACEUTICALS INC (ACAD) is a pharmaceutical preparations company, incorporated in DE. ACADIA PHARMACEUTICALS INC trades on Nasdaq as: ACAD. ACADIA PHARMACEUTICALS INC (ACAD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, ACADIA PHARMACEUTICALS INC carries a market cap of $4.34B, a P/E ratio of 11.41x, a P/B ratio of 3.32x, a P/S ratio of 3.81x, an enterprise value of $3.96B, and an EV/EBITDA multiple of 45.22x. On profitability, it posts a gross margin of 91.13%, an operating margin of 7.59%, a net margin of 33.42%, a Return on Equity (ROE) of 35.74%, a Return on Assets (ROA) of 25.64%, and a Return on Invested Capital (ROIC) of 11.26%. Per share, it reports EPS of $2.22, diluted EPS of $2.20, free cash flow per share of $0.85, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 11.75% year-over-year, net income growth of 71.27% year-over-year, and EPS growth of 67.50% year-over-year. On the balance sheet, it maintains a current ratio of 3.39x, a quick ratio of 3.20x, working capital of $863.11M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, an interest coverage ratio of 2.65x, free cash flow of $145.63M (TTM), and net debt of $-384.99M. Figures sourced from SEC EDGAR.

Market Cap

$4.34B

P/E TTM

11.41x

EPS TTM

$2.22

P/B TTM

3.32x

ROE TTM

35.74%

ROA TTM

25.64%

Debt To Equity

0.33x

Free Cash Flow TTM

$145.63M

Net Revenue TTM Growth 1Y

11.75%

Data as of 2026-06-30 · Source: SEC EDGAR